Genocea Biosciences, Inc.
GNCAQ
$0.00
$0.000.00%
OTC PK
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Revenue | 40.62% | 20.75% | 20.75% | -50.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.62% | 20.75% | 20.75% | -50.00% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 40.62% | 20.75% | 20.75% | -50.00% | -- |
| SG&A Expenses | -0.20% | 2.26% | 14.07% | 20.16% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.34% | 13.42% | 11.92% | 11.11% | -- |
| Operating Income | -22.83% | -13.20% | -11.66% | -12.37% | -- |
| Income Before Tax | 13.19% | 24.06% | 8.36% | 12.73% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.19% | 24.06% | 8.36% | 12.73% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.19% | 24.06% | 8.36% | 12.73% | -- |
| EBIT | -22.83% | -13.20% | -11.66% | -12.37% | -- |
| EBITDA | -22.77% | -12.70% | -11.38% | -12.21% | -- |
| EPS Basic | 40.18% | 58.16% | 58.27% | 61.91% | -- |
| Normalized Basic EPS | 38.41% | 56.81% | 58.26% | 61.90% | -- |
| EPS Diluted | 36.70% | 53.16% | 53.65% | 40.61% | -- |
| Normalized Diluted EPS | 38.10% | 56.70% | 58.17% | 62.54% | -- |
| Average Basic Shares Outstanding | 29.66% | 54.64% | 91.29% | 127.85% | -- |
| Average Diluted Shares Outstanding | 27.36% | 51.10% | 85.43% | 134.90% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |